RxDoctor Payments Data

Alessandra Bertolucci, MD

Ophthalmology · Clifton, NJNPI 1174528996

Payments from drug & device makers

$3,719in general payments, 2019–2025

Across 170 payments — averaging $21.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$972
  • Novartis$489
  • Bausch & Lomb Americas Inc.$436
  • Regeneron Healthcare Solutions, Inc.$413
  • Aerie Pharmaceuticals, Inc.$273
  • Sun Pharmaceutical Industries Inc.$173
  • plus $962 from 17 others

What the payments were for

  • Food & beverage$3,69799%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,719 in reported general payments places this provider in the 75th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,488,776
Medicare patients
899
Services billed
7,910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost172$87,142
RestasisCyclosporine69$56,797
XiidraLifitegrast35$35,483
Alphagan PBrimonidine Tartrate70$28,715
SimbrinzaBrinzolamide/Brimonidine Tart82$24,992
CombiganBrimonidine Tartrate/Timolol54$17,550
Brimonidine Tartrate209$12,392
RocklatanNetarsudil Mesylat/Latanoprost16$10,234
RhopressaNetarsudil Mesylate21$8,987
Restasis MultidoseCyclosporine14$8,884
Dorzolamide Hcl449$8,370
VyzultaLatanoprostene Bunod18$8,194
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol53$7,693
Latanoprost650$6,084
Cyclosporine16$5,341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan, Restasis Multidose$972$199,088379 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$436$43,67753 claims
AlconSimbrinza$76$24,99282 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$273$19,22137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Clifton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →